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ABSTRACT
Background: The 3-year results of the Symplicity HTN-1 trial 
have shown the superiority of renal sympathetic denervation 
over drug treatment in patients with resistant hypertension. 
However, the efficacy of renal sympathetic denervation was 
not confirmed by Symplicity HTN-3, the first sham-controlled 
study. Our objective was to report the safety and efficacy of 
renal sympathetic denervation using the irrigated radiofre-
quency ablation catheter in patients with resistant hypertension. 
Methods: Twenty-one patients were submitted to the procedure 
since July 2012, nine of them had a follow-up ≥ 12 months 
and were included in this analysis. The primary endpoint was 
safety, evaluated by periprocedural adverse events, renal func-
tion and renal vascular abnormalities at 6 months. Secondary 
endpoints included changes in blood pressure obtained in office 
and in the number of anti-hypertensive drugs at 12 months. 
Results: Mean age was 48.8 ± 11.7 years. In the first case, 
there was a renal artery dissection caused by the vascular 
sheath. There were no cases of thrombosis, renal infarction 
or death. Serum creatinine levels did not increase during the 
follow-up period. At 6 months, one case of significant renal 
stenosis without clinical impact was diagnosed. The average 
reduction in office blood pressure was 41.1 ± 33.2/18.6 ± 15.2 
mmHg (p  =  0.04 for systolic blood pressure and p = 0.08 
for diastolic blood pressure) and there was a mean reduction 
of 2.0 ± 2.3 in the number of anti-hypertensive drugs at 12 
months (p = 0.03). Conclusions: Renal sympathetic denervation 
using the irrigated radiofrequency ablation catheter proved to 
be feasible, safe and effective.
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RESUMO
Denervação Renal com Cateter de Ablação  
por Radiofrequência de Ponta Irrigada  
em Hipertensos Resistentes
Introdução: Resultados de 3 anos do Symplicity HTN-1 mostra-
ram superioridade da denervação simpática renal percutânea 
comparada à terapia medicamentosa em hipertensos resistentes. 
Entretanto, os desfechos de eficácia da denervação simpática 
renal percutânea no Symplicity HTN-3, primeiro ensaio con-
trolado com procedimento simulado, não foram alcançados. 
Nosso objetivo foi relatar os resultados de segurança e de 
eficácia da denervação simpática renal percutânea utilizando 
o cateter de ablação por radiofrequência de ponta irrigada em 
hipertensos resistentes. Métodos: Vinte e um pacientes foram 
submetidos ao procedimento desde julho 2012, dentre eles 
nove com seguimento ≥ 12 meses, os quais foram incluídos 
nesta análise. O desfecho primário foi a segurança, avaliada 
por eventos adversos peri-procedimento, função renal e anor-
malidade vascular renal aos 6 meses. Os desfechos secundários 
incluíram mudanças na pressão arterial obtida no consultório 
e no número de anti-hipertensivos aos 12 meses. Resultados: 
A média de idades foi 48,8 ± 11,7 anos. No primeiro caso, 
houve dissecção de artéria renal causada por trauma da 
bainha. Nenhum caso de trombose, infarto renal ou óbito foi 
observado. Não se constatou elevação dos níveis séricos de 
creatinina durante o seguimento. Aos 6 meses, diagnosticou-
se um caso de estenose significativa de artéria renal, sem 
repercussão clínica. A redução média da pressão arterial no 
consultório foi de 41,1 ± 33,2/18,6 ± 15,2 mmHg (p = 0,04 
para pressão arterial sistólica e p = 0,08 para pressão arte-
rial diastólica) e houve redução de 2,0 ± 2,3 no número de 
anti-hipertensivos aos 12 meses (p = 0,03). Conclusões: A 
denervação simpática renal percutânea, utilizando o cateter 
de ablação por radiofrequência de ponta irrigada, mostrou 
ser factível segura e eficaz.
DESCRITORES: Hipertensão. Resistência a medicamentos. 
Ablação por cateter.
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A iming to promote sympathetic nervous system activity inhibition or blockade, percutaneous renal sympathetic denervation (RSD) has emerged 
as an adjunct treatment for patients with resistant 
arterial hypertension. The medical community has 
enthusiastically followed the results of RSD since the 
publication of Schlaich et al.,1 which reported, for 
the first time, the reduction in blood pressure (BP) 
in resistant hypertensive patients (using seven differ-
ent antihypertensive agents) from 161/107 mmHg to 
127/81 mmHg after the procedure. The exponential 
growth of research and the number of publications 
related to the subject is remarkable.2 Medical device 
companies have evaluated RSD as a great innovation 
and a successful therapy for millions of patients, and 
currently there are more than 60 companies involved 
with this modality of treatment. Trials such as Symplicity 
HTN-13 and Symplicity HTN-24 showed significant 
decreases in BP, confirming the efficacy and safety of 
RSD. The three-year follow-up of Symplicity HTN-1 
disclosed the maintenance of long-term results, with 
a reduction in BP of 32/14 mmHg.5 These unpre-
cedented results exceeded those achieved with drug 
therapy and contributed to increase enthusiasm for 
the new technique.
Symplicity HTN-3, a randomized, blinded, and 
sham-controlled trial was presented at the American 
College of Cardiology Congress and published online 
in the New England Journal of Medicine on the same 
day in March 2014. Bhatt et al.6 caused controversy 
by presenting their results. At six months, the relative 
reduction in systolic BP (SBP) was similar for both 
groups (p < 0.001 for changes related to blood pres-
sure levels pre-RSD in both groups), with a difference 
between groups of only –2.39 mmHg in favor of RSD. 
In addition, a prespecified difference in SBP measured 
by 24-hour ambulatory BP monitoring (ABPM) of only 
2 mmHg was not achieved. Thus, the primary and 
secondary endpoints of RSD efficacy were not achieved 
in Symplicity HTN-3. The results contradicted most of 
previously published studies, despite a recent study 
suggesting inferiority of the RSD compared to adjusted 
drug treatment.7
Initially, the most plausible explanation for the 
unfavorable results of the Symplicity HTN-3 was the 
inclusion of a control group with sham procedure. In 
clinical trials testing medical devices and interventions, 
control with sham procedure is analogous to the use 
of a placebo in pharmaceutical trials. However, for 
ethical reasons, the control sham procedure is usually 
discouraged. Both the Symplicity HTN-1 and HTN-2 
had no control group with sham procedure.
For this reason, the placebo effect can explain all 
or most of the observed differences in BP in the first 
two trials. The lack of efficacy of RSD may also have 
been caused by incomplete or ineffective denervation. 
There is no mention of markers of RSD efficacy, such 
as microneurography and spillover of norepinephrine, 
methods that measure direct and indirect sympathetic 
activity, respectively. However, the ablation catheter 
used in Symplicity HTN-3 was also used in Symplicity 
HTN-1 and HTN-2.
In Brazil, however, catheters dedicated to RSD 
were not available until recently. Nevertheless, al-
though two systems, the Symplicity® (Medtronic®, 
Minneapolis, United States) and EnligHTN® (St. 
Jude Medical®, Minneapolis, United States), have 
already been approved by the Brazilian National 
Sanitary Surveillance Agency (Agência Nacional 
de Vigilância Sanitária – ANVISA), for clinical use, 
they are not yet routinely used in Brazil. Supported 
by the potential benefits of irrigated catheter in 
cardiac ablations, which cause deeper lesions with 
less risk of thrombus formation at the catheter tip, 
this center has been using this type of catheter for 
RSD for nearly two years, based on the hypothesis 
that irrigated-tip catheters may be beneficial in this 
context, and to evaluate the feasibility and safety 
of RSD with irrigated catheters in patients with 
resistant systemic arterial hypertension (SAH). The 
authors recently published results from the first ten 
patients undergoing the procedure; with a six-month 
follow-up.8 The present objective was to report the 
results of up to 12 months of RSD using the irrigated 
catheter in this population.
METHODS
Sample
Patients with resistant SAH followed at the Clinic 
of Nephrology and Hypertension of Instituto Dante 
Pazzanese de Cardiologia were evaluated for inclusion 
in the study. The definition of resistant hypertension 
was based on the consensus of the American Heart 
Association:9 patients should have SBP measured at the 
office > 140 mmHg, despite the use of three or more 
antihypertensive drugs, or controlled BP with ≥ four 
antihypertensive agents with synergistic action. The 
diagnosis of resistant hypertension should have been 
confirmed by at least one ABPM during follow-up.
All BP measurements were performed with an au-
tomatic brachial sphygmomanometer and in accordance 
with the standards of VI Brazilian Guidelines on Arterial 
Hypertension.10 The choice of drug treatment for BP 
control was at the discretion of the attending physi-
cian, according to the tolerance profile and associated 
comorbidities. Treatment compliance was encouraged 
in all medical appointments.
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Poor adherence to drug treatment was excluded 
by hospitalization for at least five days before surgery. 
Hospital stay was also used to supplement and update 
the investigation of secondary causes of hypertension.
The exclusion criteria comprised patients with glo-
merular filtration rate < 45 mL/min; severe liver disease; 
coagulation disorders; functional class III or IV heart 
failure (according to the functional classification of the 
New York Heart Association-NYHA); severe ventricular 
dysfunction (ejection fraction [EF] < 0.30); moderate or 
severe valvular heart disease; severe arrhythmias; acute 
myocardial infarction or stroke in the last six months; 
unresolved angina and/or myocardial ischemia; renal 
artery abnormalities (stenosis > 50%, presence of previ-
ous angioplasty or stent, solitary kidney); renal artery 
diameter < 4 mm; surgical history in the last two months; 
hypersensitivity to contrast media; suspected pregnancy; 
history of alcoholism in period of less than one year; 
mental illness that would compromise monitoring; and 
life expectancy < one year.
The protocol for this research project, as well as 
the informed consent were duly approved by the Ethics 
Committee in Research of Instituto Dante Pazzanese de 
Cardiologia. All patients signed an informed consent. 
Clinical outcomes
The primary study endpoint was the safety of the 
procedure, assessed by the rate of periprocedural adverse 
events (vascular complications at the puncture site and 
renal artery), analysis of renal function (comparison 
between baseline and six months after the interven-
tion), and occurrence of stenosis/aneurysm in the renal 
artery at six months after the intervention, assessed by 
angiography. 
Secondary endpoints comprised changes in BP 
measured at the office at 12  months of follow-up, as 
well as analysis of the procedure effect on the number 
of antihypertensive drugs used during this period.
Procedure description
Two vascular accesses were obtained by the team 
according to standardized method, one in the right 
femoral artery and another in the left femoral artery. 
The left femoral artery was used for catheter insertion 
to inject a contrast medium for renal arteriography. 
The right femoral artery was used for insertion of a 
sheath through which the Therapy Cool Point® abla-
tion catheter (St. Jude Medical®, Minneapolis, United 
States) or Celsius Thermocool® (Biosense-Webster 
Inc.®, Diamond Bar, United States) was inserted and 
placed in the renal artery. After obtaining vascular 
access, unfractionated heparin was administered at 
a dose of 100 U/kg for anticoagulation. Aortography 
along the renal arteries, followed by catheterization 
and selective renal arteriography for anatomy evalu-
ation and positioning of the ablation catheter in the 
distal portion were performed after the intravascular 
administration of nitroglycerin (200 mcg). Four to 
six sequential applications of radiofrequency were 
performed along both renal arteries to promote renal 
denervation. The catheter was retracted 5 mm and 
rotated after each application, configuring a helical 
disposition of ablations (Figure 1).
Due to intense visceral pain generated by the abla-
tion, sedation/analgesia with narcotics and opioids was 
performed in all cases. At the end of the procedure, 
renal arteriography was performed for evaluation of 
vascular integrity after intravascular administration of 
nitroglycerin (200 mcg).
Post-procedural evaluation and clinical  
follow-up
The sheaths were removed when the activated 
coagulation time reached values <  200 sec. Manual 
hemostatic compression was conducted for at least 20 
minutes, followed by compression bandage. Walking 
was permitted after four hours of rest, in the absence 
of bleeding at the puncture site. After the procedure, 
attention was given to the occurrence of vascular com-
plications at the femoral access, such as hematomas and 
pseudoaneurysms. The medications were adjusted and 
patients were advised regarding the need for regular 
monitoring.
The first return visit was conducted 7 ± 2 days 
after the procedure and aimed at evaluating puncture 
site complications, kidney function, hemoglobin/hema-
tocrit levels, and adjusting the dose of antihypertensive 
drugs. The following visits were carried out at 30 ± 7, 
90 ± 10, 180 ± 10, and 360 ± 10 days. BP measure-
ment was the same as described for the preprocedure 
evaluation. Laboratory tests were ordered at all visits. 
Angiography of the renal arteries was repeated at six 
months of follow-up. 
Statistical Analysis
Continuous variables were expressed as mean and 
standard deviation and compared using the Student’s 
t-test; categorical variables were expressed as absolute 
and relative frequencies. For all parameters, p-values 
≤ 0.05 were considered statistically significant. Data 
were analyzed using SPSS® software, version 16, for 
Windows® (SPSS® Inc., Chicago, Illinois, United States). 
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RESULTS
Clinical characteristics
Twenty-one patients underwent RSD for the ad-
junct treatment of resistant SAH. Among them, nine 
patients (eight women) with follow-up ≥ 12 months 
were included in this analysis. The mean age was 48.8 
± 11.7 years. The mean time from diagnosis of SAH was 
18.1 ± 11.3 years. Mean SBP and diastolic BP (DBP) 
measures at the office were 202.8 ± 32.5 mmHg and 
116.2 ± 18.7 mmHg, respectively. The mean number 
of anti-hypertensive drugs before the procedure was 
7.7 ± 1.3. The clinical characteristics of the patients 
are shown in Table 1.
Angiographic characteristics
The mean diameters of the left and right renal ar teries 
were 5.0 ± 0.4 mm and 5.0 ± 0.7 mm, respectively. 
The mean length of the left and right renal arteries 
was 33.7 ± 7.0 mm and 26.4 ± 10.3 mm, respectively. 
One case had one polar artery on the left, and 
another, three polar arteries were observed, two on the 
left and one on the right. Two patients had mild proximal 
renal artery stenosis (Table 2).
Table 1 
Basal characteristics
Variable n = 9
Age, years 48.8 ± 11.7
Body mass index, kg/m2 29.9 ± 3.9
Diabetes mellitus, n (%) 3 (33.3)
Dyslipidemia, n (%) 7 (77.8)
Smoking, n (%) 0
Alcohol consumption, n (%) 0
Previous MI, n (%) 0
Previous stroke, n (%) 0
Peripheral vascular disease, n 
(%)
0
Family history of SAH, n (%) 8 (88.9)
Basal creatinine, mg/dL 0.96 ± 0.29
Time of SAH diagnosis, years 18.1 ± 11.3
SBP/DBP measured at the office, 
mmHg
202.8 ± 
32.5/116.2 ± 18.7
MI, myocardial infarction; SAH, systemic arterial hypertension; 
SBP, systolic blood pressure; DBP, diastolic blood pressure.
A
D
B
E
C
F
Figure 1 – Sequential radiofrequency lesions in the renal artery. (A) Selective angiography of the left renal artery; (B to F) sequential applications 
initiated in the distal segment; the catheter was retracted and rotated after each application to promote sequential lesions with helical configuration.
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Technical characteristics of the procedure
All procedures were performed via transfemoral 
access according to the protocol described herein. On 
average, 76.7 ± 25.4 mL of contrast medium was used 
for 19.7 ± 6.2 minutes of fluoroscopy. The mean num-
ber of RF applications was 5.2 ± 0.7 in the right renal 
artery and 4.3 ± 1.7 in the left renal artery (Table 2).
Safety of the procedure
The procedure was performed without complica-
tions in eight cases. In the first case of this series, a 
renal artery dissection was detected after the ablation 
was performed due to mechanical trauma caused by 
the sheath. She was treated with stenting without sub-
sequent increase in complications or hospital stay. At 
six months, renal arteriography showed patency and 
no significant in-stent hyperplasia.
Focal parietal irregularities in the renal artery were 
observed in some cases immediately after radiofrequency 
application, having been attributed to spasms and/or 
edema. None was considered limiting to blood flow 
after the procedure.
There were no complications related to femoral 
puncture during the periprocedural period. There was no 
increase in serum creatinine (basal 0.96 ± 0.29 mg/ dL vs. 
0.93 ± 0.32 mg/dL at 6 months), indicating maintenance 
of glomerular filtration rate during follow-up (Figure 2).
Renal vascular safety
Renal arteriography was performed in all patients 
at six months follow-up. In one case, there was evi-
dence of significant degree of left renal artery stenosis 
(70%). Although it had no clinical significance, it was 
uneventfully treated with stent implant.
Effects on blood pressure and number of 
antihypertensive drugs at 12 months
After 12 months of follow-up, RSD reduced BP 
measured at the office, on average, by 41.1 ± 32.2/18.6 
± 15.2 mmHg (p = 0.04 for SBP, and p = 0.08 for DBP) 
(Figure 3). There was a mean reduction of 2 ± 2.3 anti-
hypertensive drugs prescribed at 12 months (basal 7.7 
± 1.3 vs. 5.7 ± 2.2 at 12 months, p = 0.03) (Figure 4). 
Anti-hypertensive response was observed in eight 
(88.9%) patients, with a reduction of up to 104 mmHg 
for SBP. Only one patient did not show a reduction in 
BP levels. A reduction of up to six anti-hypertensive 
drugs at the 12-month follow-up was also observed.
DISCUSSION
This study was conducted at a tertiary cardiology 
center, which used irrigated ablation catheter for 
radiofrequency application in the context of RSD in 
patients with resistant hypertension. The results showed 
that ablation of the renal sympathetic activity using an 
irrigated catheter is feasible, safe, and effective. 
The procedure reduced SBP and DBP measured in 
the office, on average, by 41.1 ± 32.2 mmHg and 18.6 
± 15.2 mmHg, respectively. There was a mean reduction 
of 2 ± 2.3 anti-hypertensive drugs. A reduction of up to 
six anti-hypertensive drugs and up to 104 mmHg in SBP 
was observed during follow-up. Symplicity HTN-3 did 
not report changes in the number of anti-hypertensive 
drugs, and the mean reduction in SBP was only 2.4 
mmHg compared to the control group.
The SBP decrease in Symplicity HTN-3 was observed 
both in the RSD group and in the control group – a 
divergent finding when compared to previous studies; 
moreover, the decrease was approximately half of that 
observed in the Symplicity HTN-2, despite the fact 
that the basal blood pressures were similar in the two 
studies. This is intriguing, as the degree of BP reduc-
tion is related to pretreatment BP levels. Comparison 
between the control groups of the Symplicity HTN-3 
and HTN-2 studies shows a greater reduction in BP 
in the former study. It is plausible that greater expo-
sure to spironolactone (28.7% vs. 17% of patients) in 
Sympli city HTN-3 facilitated this decrease. Differently 
Table 2  
Angiographic and technical characteristics  
of the procedure
Variable n = 9
Diameter of RRA/LRA, mm 5.0 ± 0.4/5.0 ± 0.7
Extension of RRA/LRA, mm 33.7 ± 7.0/26.4 ± 10.3
Contrast volume, mL 76.7 ± 25.4
Time of fluoroscopy, min 19.7 ± 6.2
Number of radiofrequency 
applications on RRA/LRA
5.2 ± 0.7/4.3 ± 1.7
RRA, right renal artery; LRA, left renal artery.
Cr
ea
tin
in
e 
(m
g/
dL
)
0.96 ± 0.29
2
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0.93 ± 0.32
Basal Six months
Figure 2 – Effects of renal sympathetic denervation on serum creatinine 
in the first six months of evolution.
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from the mentioned trials, most patients in the present 
population were taking spironolactone (88.9%).
The great variability in response to RSD raises the 
question of how this procedure could be more effective 
in selected patients, especially those with sympathetic 
hyperactivity. The rate of non-responders to treatment 
with RSD (defined as reduction in SBP < 10 mmHg six 
months after the procedure) varies from 8% to 37% in 
the main clinical trials. The causes of this finding are not 
yet fully understood; however, some assumptions can 
be made based on knowledge of the physiopathology 
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Figure 3 – On the left, effect of renal sympathetic denervation on blood pressure (BP) measured in the office. On the right, effect of renal sympa-
thetic denervation on systolic blood pressure (SBP) measured in the office in each of the nine patients submitted to the procedure. DBP, diastolic 
blood pressure.
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Figure 4 – On the left, renal sympathetic denervation effect on the mean number of antihypertensive drugs. On the right, effect of renal sympathetic 
denervation on the number of antihypertensive drugs in each of the nine patients submitted to the procedure.
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of SAH and the RSD procedure. Among them, the 
following are emphasized: (1) significant variability 
of devices and techniques, including RF power used, 
number of electrodes, and duration of ablation; (2) the 
actual relevance of sympathetic hyperactivity in the 
physiopathology of resistant hypertension, as this is a 
multifactorial disease and, in some cases, the sympathetic 
nervous system contribution may not be as important 
for disease expression; (3) the inadequate selection 
of patients, including patients with pseudo-resistance 
and secondary hypertension; and (4) patient-related 
conditions such as non-adherence to pharmacological 
treatment and failure to change lifestyle. The standard 
deviations of changes in the initial SBP measured at 
the office for both groups (RSD and control) in Sym-
plicity HTN-1 and HTN-2 were broad and very similar, 
indicating a large variation in response. The change 
in SBP in 95% of patients in Symplicity HTN-2 was 
between –78 mmHg and 14 mmHg in the RSD group, 
and between –43 mmHg and 41 mmHg in the control 
group. In Symplicity HTN-3, the mean BP reduction was 
also within this range for both groups. In the present 
population, the standard deviation was 33.2 mmHg and 
the change in SBP ranged between –104 mmHg and 
9 mmHg. A satisfactory response was not obtained in 
only one patient (11.1%).
Other differences between Symplicity HTN-3 and 
the present study deserve to be mentioned. First, the 
present patients needed a greater number of anti-
hypertensive drugs at baseline (7.6 ± 1.3 vs. 5.1 ± 1.4). 
Second, due to the smaller number of patients, it was 
possible to confirm resistant SAH based on hospital 
admissions, while Symplicity HTN-3 established the 
diagnosis in outpatient consultations, which may have 
overestimated basal blood pressure levels. Third, in 
Symplicity HTN-3, changes in doses of anti-hypertensive 
drugs were allowed only if the patient had symptoms 
related to hypotension. In the present study, the drug 
dose was changed aiming at the control recommended 
by the VI Brazilian Guidelines on Hypertension;10 in 
patients in whom baseline BP was controlled with 
four or more antihypertensive drugs, there was no 
significant reduction in BP, but a decrease in the 
number of drugs at the follow-up. Finally, the present 
study used a nondedicated catheter for RSD – the ir-
rigated tip catheter designed for cardiac ablation. It is 
believed this represents the major difference regarding 
the present study’s approach to RSD, allowing for the 
achievement of superior results.
The authors have published the effects of three dif-
ferent catheters, usually used for cardiac ablation, in an 
in vitro experiment with porcine renal arteries.11 It was 
verified that the irrigated catheter (usually indicated for 
ablation of arrhythmias in heart chambers located on the 
left) results in deeper lesions, causing full destruction of 
nerves, useful for promoting the ablation of those located 
beyond 4 mm of the arterial intimal layer, which can 
comprise up to 40% of the nerves in the renal arteries. 
These results were consistent with those published by 
Ahmed et al.,12 who described ten patients with resis-
tant SAH submitted to RSD with irrigated catheter. The 
authors demonstrated reductions in SBP and DBP of 21 
and 11 mmHg, respectively, at six months of follow-up, 
as well as absence of severe complications.
The enthusiasm about RSD has been widespread, 
as shown by the statements: “the potential of renal 
denervation is huge” and “it can be used not only to 
treat hypertension, but also diseases that are character-
ized by sympathetic overactivity, such as diabetes and 
hyperinsulinemia, heart failure, arrhythmias, and chronic 
renal failure”.13 These carefully phrased words mention 
the benefits of renal denervation for these metabolic or 
cardiovascular alterations. In contrast, the current findings 
of Symplicity HTN-3 by the same authors, six months 
later, attest that “no significant effect was observed on 
SBP”. Additional assessment in strictly designed clini-
cal trials will be necessary to confirm the previously 
reported benefits of RSD in patients with resistant SAH. 
The unanswered question is what the real role of RSD 
is as an adjunct treatment in SAH. Science requires 
caution and time will answer this question. 
Limitations 
Among the main limitations of this study are its 
nonrandomized design, the small sample size, and lack 
of a control group. Despite these limitations, the results 
appear promising and are consistent with the existing 
literature. Randomized controlled trials with a sham 
procedure are necessary to confirm the present results. 
CONCLUSIONS 
Percutaneous RSD using the irrigated radiofrequency 
ablation catheter proved to be feasible, safe, and effective.
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